Premium
New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia
Author(s) -
del Campo Marta,
Zetterberg Henrik,
Gandy Sam,
Onyike Chiadi U,
Oliveira Fabricio,
UdehMomoh Chi,
Lleó Alberto,
Teunissen Charlotte E.,
Pijnenburg Yolande
Publication year - 2022
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.12643
Subject(s) - frontotemporal dementia , disease , biomarker , clinical trial , medicine , dementia , observational study , biomarker discovery , intensive care medicine , bioinformatics , pathology , biology , biochemistry , gene , proteomics
Frontotemporal dementia (FTD) covers a spectrum of neurodegenerative disorders with different phenotypes, genetic backgrounds, and pathological states. Its clinicopathological diversity challenges the diagnostic process and the execution of clinical trials, calling for specific diagnostic biomarkers of pathologic FTD types. There is also a need for biomarkers that facilitate disease staging, quantification of severity, monitoring in clinics and observational studies, and for evaluation of target engagement and treatment response in clinical trials. This review discusses current FTD biofluid‐based biomarker knowledge taking into account the differing applications. The limitations, knowledge gaps, and challenges for the development and implementation of such markers are also examined. Strategies to overcome these hurdles are proposed, including the technologies available, patient cohorts, and collaborative research initiatives. Access to robust and reliable biomarkers that define the exact underlying pathophysiological FTD process will meet the needs for specific diagnosis, disease quantitation, clinical monitoring, and treatment development.